De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ocular Therapeutix Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Ocular Therapeutix de winst en omzet met respectievelijk 16.7% en 32.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 20.8% per jaar.

Belangrijke informatie

16.7%

Groei van de winst

20.8%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.5%
Inkomstengroei	32.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	01 Oct 2024

Recente toekomstige groei-updates

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10

Recent updates

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Jul 23

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Jul 15

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Jun 05

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 01

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Aug 15

Winst- en omzetgroeiprognoses

NasdaqGM:OCUL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	95	-149	-113	-129	6
12/31/2025	75	-162	-138	-123	8
12/31/2024	66	-180	-144	-125	8
6/30/2024	61	-138	-91	-89	N/A
3/31/2024	60	-115	-87	-84	N/A
12/31/2023	58	-81	-76	-70	N/A
9/30/2023	58	-67	-73	-65	N/A
6/30/2023	55	-91	-78	-70	N/A
3/31/2023	52	-89	-68	-61	N/A
12/31/2022	51	-71	-63	-60	N/A
9/30/2022	50	-59	-60	-58	N/A
6/30/2022	50	-33	-59	-58	N/A
3/31/2022	49	-22	-68	-67	N/A
12/31/2021	44	-7	-67	-66	N/A
9/30/2021	39	-88	-57	-57	N/A
6/30/2021	32	-103	-58	-57	N/A
3/31/2021	22	-131	-53	-52	N/A
12/31/2020	17	-156	-54	-54	N/A
9/30/2020	12	-96	-68	-67	N/A
6/30/2020	7	-103	-74	-73	N/A
3/31/2020	6	-91	-79	-77	N/A
12/31/2019	4	-86	-80	-78	N/A
9/30/2019	2	-78	-74	-72	N/A
6/30/2019	2	-74	-65	-63	N/A
3/31/2019	2	-63	-58	-56	N/A
12/31/2018	2	-60	-51	-49	N/A
9/30/2018	2	-56	-48	-46	N/A
6/30/2018	2	-56	-53	-49	N/A
3/31/2018	2	-61	N/A	-48	N/A
12/31/2017	2	-63	N/A	-50	N/A
9/30/2017	2	-63	N/A	-48	N/A
6/30/2017	2	-57	N/A	-41	N/A
3/31/2017	2	-50	N/A	-39	N/A
12/31/2016	2	-45	N/A	-34	N/A
9/30/2016	2	-43	N/A	-35	N/A
6/30/2016	2	-44	N/A	-37	N/A
3/31/2016	2	-43	N/A	-36	N/A
12/31/2015	2	-40	N/A	-34	N/A
9/30/2015	2	-37	N/A	-31	N/A
6/30/2015	2	-33	N/A	-27	N/A
3/31/2015	1	-29	N/A	-23	N/A
12/31/2014	1	-29	N/A	-20	N/A
9/30/2014	0	-24	N/A	-18	N/A
6/30/2014	0	-20	N/A	-15	N/A
3/31/2014	0	-17	N/A	-13	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat OCUL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat OCUL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat OCUL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van OCUL ( 32.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van OCUL ( 32.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van OCUL naar verwachting over 3 jaar hoog zal zijn

Ocular Therapeutix Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Consensus EPS estimates fall by 23%

Consensus EPS estimates fall by 29%

Consensus EPS estimates upgraded to US$0.67 loss, revenue downgraded

Price target decreased by 9.7% to US$11.86

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Ocular Therapeutix, Inc. Announces Fda Feedback That Sol-R Trial Is Appropriate as A Registrational Study in Wet Amd

Ocular Therapeutix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Ocular Therapeutix, Inc. Announces First Patients Enrolled in Phase 3 Sol-R Wet AMD Study

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Executive Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 23%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Consensus EPS estimates fall by 29%

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Consensus EPS estimates upgraded to US$0.67 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

President notifies of intention to sell stock

President recently sold US$91k worth of stock

President notifies of intention to sell stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Price target decreased by 9.7% to US$11.86

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

New minor risk - Share price stability

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

New minor risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.8% to US$12.63

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

President notifies of intention to sell stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 13%

Insufficient new directors

Price target decreased to US$13.29

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD